false 0000027367 0000027367 2023-10-27 2023-10-27 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported) October 27, 2023

 

Daxor Corporation

 

(Exact name of registrant as specified in its charter)

 

New York   811-22684   13-2682108
(State or other jurisdiction   (Commission   (IRS Employer
of incorporation)   File Number)   Identification No.)

 

 109 Meco Lane, Oak Ridge, TN   37830
(Address of principal executive offices)   (Zip Code)

 

212-330-8500

 

Registrant’s telephone number, including area code

 

 

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange

 

Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock $0.01 par value   DXR   NYSE AMERICAN

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 

 

 

 
 

 

Item 8.01Other Events

 

Daxor Corporation (the “Company”) is filing this Current Report on Form 8-K to provide additional information regarding the use of proceeds from its public offering on May 22, 2023. In the offering, the Company raised net proceeds of $3,555,532 through the issuance of 410,260 shares at $9.75 per share. More information regarding the offering is available in the Prospectus Supplement filed with the Securities and Exchange Commission under Rule 497 of the Securities Act on May 23, 2023, and the Prospectus Supplement is incorporated by reference herein.

 

The offering documents cited next generation technology development as a potential use of proceeds, among other potential uses. In this regard, the Company hereby announces that it has reserved $1,900,000 of the net proceeds from the May 22, 2023 public offering to support the continued development of its next generation optical blood volume analyzer systems.

 

The Company anticipates that development work will proceed over a 24 month period, and expects it will be done in conjunction with other technology development efforts supported by the Department of Defense. The Company is excited to be moving forward its next generation technologies.

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

 

  DAXOR CORPORATION
  (Registrant)
   
Date: October 27, 2023 By: /s/ Robert J. Michel
  Name: Robert J. Michel
  Title: Chief Financial Officer

 

 

v3.23.3
Cover
Oct. 27, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Oct. 27, 2023
Entity File Number 811-22684
Entity Registrant Name Daxor Corporation
Entity Central Index Key 0000027367
Entity Tax Identification Number 13-2682108
Entity Incorporation, State or Country Code NY
Entity Address, Address Line One 109 Meco Lane
Entity Address, City or Town Oak Ridge
Entity Address, State or Province TN
Entity Address, Postal Zip Code 37830
City Area Code 212
Local Phone Number 330-8500
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock $0.01 par value
Trading Symbol DXR
Security Exchange Name NYSE
Entity Emerging Growth Company false

Daxor (NASDAQ:DXR)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Daxor Charts.
Daxor (NASDAQ:DXR)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Daxor Charts.